UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

IN RE: PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

MDL NO. 1456

THIS DOCUMENT RELATES TO:

CIVIL ACTION: 01-CV-12257-PBS

ALL ACTIONS

Judge Patti B. Saris

DECLARATION OF STEVE W. BERMAN IN SUPPORT OF LEAD CLASS COUNSEL'S OPPOSITION TO THE WILLIAMS MOTION TO COMPEL DISCLOSURE OF FEE SETTLEMENT AGREEMENT WITH KLINE & SPECTER

I, Steve W. Berman, duly declare as follows:

I am a partner of Hagens Berman Sobol Shapiro LLP, resident in its Seattle,
 Washington, office, and I am co-lead counsel for the Plaintiffs in the above-captioned matter. I
 submit this declaration in support of Lead Class Counsel's Opposition to the Williams Motion to

Compel Fee Settlement Agreement With Kline & Specter.

2. Attached as Exhibit A is a true and correct copy of excerpted pages from the

November 11, 2011 Hearing Transcript.

I certify under penalty of perjury that the foregoing is true and correct.

Executed this 1st day of February, 2013.

/s/ Steve W. Berman STEVE W. BERMAN

CERTIFICATE OF SERVICE

I hereby certify that I, Steve W. Berman, an attorney, caused a true and correct copy of the foregoing, **LEAD CLASS COUNSEL'S OPPOSITION TO THE WILLIAMS MOTION TO COMPEL FEE SETTLEMENT AGREEMENT WITH KLINE & SPECTER**, to be delivered to all counsel of record by electronic service pursuant to Paragraph 11 of the Case Management Order No. 2, by sending on February 1, 2013, a copy to LEXISNexis File & Serve for posting and notification to all parties.

<u>/s/ Steve W. Berman</u>
Steve W. Berman

Exhibit A

	Page 1
1	IN THE UNITED STATES DISTRICT COURT
	FOR THE DISTRICT OF MASSACHUSETTS
2	
3	IN RE:
) CA No. 01-12257-PBS
4	PHARMACEUTICAL INDUSTRY AVERAGE)
	WHOLESALE PRICE LITIGATION) Pages 1 - 35
5)
6	
7	
8	
	TRACK TWO FAIRNESS HEARING
9	
	BEFORE THE HONORABLE PATTI B. SARIS
10	UNITED STATES DISTRICT JUDGE
11	
12	
13	
14	
	United States District Court
15	1 Courthouse Way, Courtroom 19
	Boston, Massachusetts 02210
16	November 22, 2011, 2:57 p.m.
17	
18	
19	
20	
21	
22	LEE A. MARZILLI
	OFFICIAL COURT REPORTER
23	United States District Court
	1 Courthouse Way, Room 3205
24	Boston, MA 02210
	(617)345-6787
25	

1

2

3

4

5

6

7

11

13

14

16

17

18

19

20

21

22

23

24

25

8

9

15

16

17

18

19

20

21

Page 26

1 MS. BALDWIN: The majority of the claims have been 2 dismissed.

3 THE COURT: In light of this case?

9

10

13

14

15

16

17

21

22

1

7

8

9

10 11

12

13

14

15

16

17

18

19

20

21

22

23

24

4 MS. BALDWIN: In light of this case. Your Honor entered orders -- I believe I can give you approximate dates. 5 Well, around November of 2007 and March of 2009, the majority 6 7 of the claims in those cases were dismissed because of orders 8 entered here.

MR. MATT: Those may have been as part of settlements. I'm just not familiar with it, your Honor.

11 MS. BALDWIN: And, your Honor, as part of the 12 settle- --

THE COURT: Did you get money from those?

MS. BALDWIN: No, your Honor. We didn't seek any fees in any of those cases, with the understanding that we had with lead counsel that we would be compensated here.

THE COURT: Who's lead counsel?

18 MS. BALDWIN: I believe the majority of our dealings 19 were with Mr. Edelson, but it was members of the Fee Committee. 20

THE COURT: Well, this may turn seemingly unfortunate if in fact it turns into depositions and fact disputes over whether or not there was a binding oral agreement.

23 MS. BALDWIN: There was an e-mail exchange between 24 Shanin Specter of my office and Steve Berman and Tom Sobol

25 dated October 15 of 2005. That's attached as Exhibit A to

MS. BALDWIN: Well, the drugs that we were -- we adopted a strategy with the lead counsel to conduct discovery in those cases for the benefit of the class here, and lead counsel has put in pleadings with this court --

Page 28

THE COURT: But I wouldn't pay you a penny, let me just say this, out of this class money unless it involves the drugs involved in this case and there was some value added.

8 MS. BALDWIN: I understand, your Honor, and --9 THE COURT: So it can't be some drug that's not part 10

of my class approval. MS. BALDWIN: I understand, your Honor, and lead 12 counsel has submitted in filings with this Court that our state court work was of value to members of the class, it was authorized by them, and that it actually did benefit the

15 members of the class.

> THE COURT: Did it benefit the members of the other classes you're pursuing as well?

MS. BALDWIN: No, your Honor. Those claims have virtually all been dismissed for the sake of the class members

THE COURT: Well, this is a mess, as you can imagine, and it will end up holding up these attorneys' fees; but I am not holding up this class settlement, and I will be imposing an appeal bond. This case has taken way too long, way too long, and these people need this money. As you pointed out, some

Page 27

Mr. Williams' memorandum and --

2 THE COURT: What did Mr. Berman say or Mr. Sobol? 3 MR. MATT: Those e-mails, your Honor -- I've reviewed 4 them briefly -- they are negotiations.

5 THE COURT: Well, I don't know.

6 MR. MATT: And there is no agreement.

THE COURT: I say, at the end of this day, won't we be sorry campers if it takes me another two years to figure out the attorneys' fees issue by sitting here and either doing a master's hearing or a magistrate judge's hearing or me myself holding a little trial? I think it's worth trying to figure out. Why do you think you get lodestar? I don't even give them lodestar.

MS. BALDWIN: Well, your Honor, the point is, we want some allocation for the state time, and I'm just giving you what our total lodestars are; but right now it appears as though lead counsel wants to subtract out all of our work for the state time, so I'm telling you what our lodestar and expenses were in those cases.

THE COURT: And just on these drugs, or is it on the whole litigation?

MS. BALDWIN: It would be in each of those state court actions.

THE COURT: I wouldn't do that either because it's only the drugs that we're talking about here.

Page 29

1 class reps have died already; and some people are not very 2 sick, but there are a lot of people who are very sick, and I

3 want the money out. And I'm trying to figure out what to do in

4 terms of alerting the -- have you had success, any of the

5 parties here, in alerting the First Circuit to how important it

6 is not to take a year? Is there a way of expediting the

7 appellate process through a motion?

MR. MATT: My recollection is, we did try that in GSK, and it was denied.

10 THE COURT: A motion to expedite?

11 MR. MATT: Yes.

12 THE COURT: I think you have a lot of judges on the 13 First Circuit who, unfortunately for them, are now very 14 familiar with this litigation.

MR. MATT: We can try again.

THE COURT: It may be worth the effort if everybody here signed onto it. That's not the attorneys' fees piece. So let me just ask you this. I've got these motions. I've heard enough to know that it's going to take a while. Does it make some sense to do depositions? Do you want me to refer it to a magistrate judge for fact finding?

22 MR. MATT: Let's keep it here for now, your Honor. We 23 haven't started writing our opposition brief yet.

24 THE COURT: It's in everyone's interest to move this 25 along quickly. And I don't know if you know, but, as you know,

1 2

3

9

10

11

12

15

16

17

18

19

23

4

12

13

14

15

Page 30

I now have a job in Washington as well. I'm now carrying two jobs, and it's just not going to be guick. I don't have time 2 3 to even slot you in.

MR. MATT: Understood, your Honor. Another thing we can do is, we can set aside the amount that's in dispute and perhaps do another attorneys' fee distribution. So there's ways to --

THE COURT: If you do my percentages and this number, how much money are you entitled to?

MR. MATT: For Track Two settlement?

11 THE COURT: Yes.

4

5 6

7

8 9

10

12 13

14

15

17

18

19

20

21

1

2

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

figure it out.

MR. MATT: I can tell you exactly actually. If you sign onto the order, there will be \$37 million for Track Two.

THE COURT: Well, so why don't we just, you get paid, I don't know, assuming -- we still have the appeal issue. Once the appeal is finalized, you'd get all but whatever they're asking for in attorneys' fees and expenses, and I hold that in escrow in the court, because you're getting a lot of money.

MR. EDELSON: Your Honor, as Mr. Matt pointed out, the majority of money they're seeking is for an Arizona state Lupron case, which has nothing to do with this at all.

22 MR. MATT: Lupron was never at issue in this case.

23 THE COURT: Right, so that would go away.

24 So are you pressing Lupron money?

25 MR. EDELSON: Yes.

Page 32 MS. BALDWIN: Your Honor, I think that they should be entitled to the right to respond, and I think that perhaps the attorneys talking might be the first step.

4 THE COURT: Well, both, but I'm simply saying, you are 5 both going to spend a long time waiting for this. But I am 6 telling you, at least unless I see it differently -- I haven't 7 read your motion yet -- it's only going to be for drugs 8 involved in this litigation.

MS. BALDWIN: I understand, your Honor, and many of these drugs were in this litigation, and lead counsel understood that our work was to benefit the class members of this litigation.

13 MR. MATT: We dispute that, your Honor, but we'll 14 brief it.

THE COURT: Yes, you will, and then it's going to take a lifetime. But, then again, you may be waiting for the appeal anyway, so, so be it.

MR. MATT: We've heard you loud and clear. Thank you. THE COURT: Okay. Did you want to say something?

20 You're sitting there poking up every once in a while.

21 MS. BALDWIN: Your Honor, there was a joinder to our 22 motion filed by Mr. Levy.

MR. LEVY: I just wanted to get that on the record,

24 your Honor, because my name wasn't mentioned. My name is Adam

25 Levy. I had filed a --

MS. BALDWIN: Well, your Honor, if you're going to say that's going away, that's fine, but what's really important to us would be the coordinated AWP actions, which would be the ones filed -- in Arizona there was an AWP action, and in New Jersey there was an AWP action, and we have a plethora of e-mails between the signatories and lead counsel on the strategy.

THE COURT: That may be, but on this class that I fought so hard to get just right, I am not going to be

providing attorneys' fees for drugs that were not involved in this litigation.

MS. BALDWIN: Understood, your Honor.

THE COURT: If there's a way of allocating drugs involved in this litigation, and if there was some sort of oral understanding, or misunderstanding, whichever way it goes, and you dismiss, which is they're relying to their detriment -- I know these firms. I know your firms. You don't just dismiss without some quid pro quo. You just don't. They must have understood something was about to happen. And so if you carve off Lupron, if you carve off other drugs that aren't involved with this, and any money, you know, for drugs that are still poking along in New Jersey, there may be a basis for a

settlement. Otherwise, I'll take your -- why don't you -- it's 3:30. Do you want this courtroom? Sit and schmooz and try and

1 THE COURT: Where are you from?

> 2 MR. LEVY: Where am I from? I'm from outside of 3 Philadelphia, your Honor.

> > THE COURT: I recognize that accent. Okay.

5 MR. LEVY: I've actually been here, and one of the 6 witnesses that I helped prepare testified here in the BMS 7

trial. But that was a long time ago, and yet I'm back, Adam 8 Levy, and I joined in the motion for the fees and expenses from

9 the state court cases. So I just wanted you --

10 THE COURT: Was that in addition to the \$2 million she 11 mentioned, or the \$2 million is an aggregate --

MR. LEVY: I don't know if that was --

MS. BALDWIN: His numbers were not included because he wasn't a signatory to our motion, so his would be in addition to our numbers.

16 THE COURT: And how much are you talking about? 17 MR. LEVY: About \$400,000 of time. That's lodestar, 18 your Honor.

19 THE COURT: And did you rely on any promises? 20 MR. LEVY: I was actually named in the agreement 21 that -- between the e-mails that went back and forth between

Mr. Specter and Mr. Berman, my name is actually in the 22 23 agreement along with the other gentlemen whose firms are --

24 THE COURT: So answer is "yes," you believe that you 25 were an intended beneficiary?

Page 33